Ethically justified, clinically applicable criteria for physician decision-making in psychopharmacological enhancement

Neuroethics

Volumn 2, Issue 2, 2009, Pages 89-102

  Synofzik, Matthis ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Drugs; Ethics; Neuroenhancement; Physician; Psychopharmacology

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; ANTILIPEMIC AGENT; METHYLPHENIDATE; MODAFINIL; NOOTROPIC AGENT; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BENEFICENCE; CHROMOSOME ABERRATION; COGNITION; COGNITIVE DEFECT; DEPRESSION; DOCTOR PATIENT RELATION; DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG SAFETY; HEALTH CARE PERSONNEL; HEALTH STATUS; HUMAN; HYPERCHOLESTEROLEMIA; MEDICAL DECISION MAKING; MEDICAL ETHICS; MILD COGNITIVE IMPAIRMENT; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; QUALITY OF LIFE; REVIEW;

EID: 62349093739     PISSN: 18745490     EISSN: 18745504     Source Type: Journal    
DOI: 10.1007/s12152-008-9029-1     Document Type: Review

References (54)

1. Elliott, C. 2003. Better than well: American medicine meets the American dream. New York: Norton.
2. M.J. Farah J. Illes R. Cook-Deegan H. Gardner, et al. 2004 Neurocognitive enhancement: what can we do and what should we do? Nature Reviews Neuroscience 5 421 425 10.1038/nrn1390
3. M. Sullivan 2003 The new subjective medicine: taking the patient's point of view on health care and health Social Science & Medicine 56 1595 1604 10.1016/S0277-9536(02)00159-4
4. Synofzik, M. 2005. Measuring the unmeasurable? Quality of life and medical decision making. Virtual Mentor. Ethics Journal of the AMA 7. http://virtualmentor.ama-assn.org/2005/02/pdf/fred1-0502.pdf. Accessed 12/05/08.
5. P. Whitehouse E. Juengst M. Mehlman T. Murray 1997 Enhancing cognition in the intellectually intact Hastings Center Report 27 14 22
6. Parens, E. (Ed.), 1998. Enhancing human traits. Ethical and social implications. Washington: Georgetown University Press.
7. M.J. Mehlman 2004 Cognition-enhancing drugs Milbank Quarterly 82 483 506 10.1111/j.0887-378X.2004.00319.x
8. A. Chatterjee 2004 Cosmetic neurology: the controversy over enhancing movement, mentation, and mood Neurology 63 968 974
9. B. Sahakian S. Morein-Zamir 2007 Professor's little helper Nature 450 1157 1159 10.1038/4501157a
10. Juengst, E.T. 1998. What does enhancement mean? In Enhancing human traits. Ethical and social implications, ed. E. Parens, 29-47. Washington: Georgetown University Press.
11. Synofzik, M. 2008. Psychopharmakologisches Enhancement: Ethische Kriterien jenseits der Treatment-Enhancement-Unterscheidung. In Neuro-Enhancement. Ethik vor neuen Herausforderungen, eds. D. Talbot, B. Schöne-Seifert, J. Ach, and U. Opolka. Paderborn: Mentis.
12. Fukuyama, F. 2002. Our posthuman future. New York: Farrar, Straus & Giroux.
13. Sandel, M.J. 2007. The case against perfection: Ethics in the age of genetic engineering. Cambridge: Harvard University Press.
14. M. Synofzik 2006 Effective, indicated-and yet without benefit? The goals of dementia drug treatment and the well-being of the patient Zeitschrift fūr Gerontologie und Geriatrie 39 301 307 10.1007/s00391-006-0390-6
15. U. Wiesing 1998 Kann die Medizin als praktische Wissenschaft auf eine allgemeine Definition von Krankheit verzichten Zeitschrift für Medizinische Ethik 44 83 97
16. G. Hesslow 1993 Do we need a concept of disease Theoretical Medicine 14 1 14 10.1007/BF00993984
17. C. Boorse 1977 Health as a theoretical concept Philosophy of Science 44 542 573 10.1086/288768
18. Lenk, C. 2008. Veränderung kognitiver Merkmale und das Argument der "Offenheit des Lebensweges". In Neuro-Enhancement. Ethik vor neuen Herausforderungen, eds. D. Talbot, B. Schöne-Seifert, J. Ach, and U. Opolka. Paderborn: Mentis.
19. Daniels, N. 1985. Just health care. Cambridge, MA: CUP.
20. J.E. Sabin N. Daniels 1994 Determining "medical necessity" in mental health practice Hastings Center Report 24 5 13
21. N. Daniels 2000 Normal functioning and the treatment-enhancement distinction Cambridge Quarterly of Healthcare Ethics 9 309 322 10.1017/S0963180100903037
22. R.C. Petersen G.E. Smith S.C. Waring R.J. Ivnik, et al. 1999 Mild cognitive impairment: clinical characterization and outcome Archives of Neurology 56 303 308 10.1001/archneur.56.3.303
23. R. Moynihan I. Heath D. Henry 2002 Selling sickness: the pharmaceutical industry and disease mongering BMJ 324 886 891 10.1136/bmj.324.7342.886
24. R. Moynihan D. Henry 2006 The fight against disease mongering: generating knowledge for action PLoS Medicine 3 e191 10.1371/journal.pmed.0030191
25. R. Moynihan E. Doran D. Henry 2008 Disease mongering is now part of the global health debate PLoS Medicine 5 e106 10.1371/journal.pmed.0050106
26. Neuroinvestment. Cortex Comments. 2005. http://www.neuroinvestment.com/ CORXcom.html. Accessed 16 May 2008.
27. Parens, E. 2005. Creativity, gratitude, and the enhancement debate. In Neuroethics. Defining the issues in theory, practice and policy, ed. J. Illes, 75-86. Oxford: OUP.
28. Hanson, M.J., and D. Callahan. (Eds.), 1999. The goals of medicine: The forgotten issues in health care reform. Washington, DC: Georgetown University Press.
29. Schermer, M., I. Bolt, R. De Jongh, and B. Olivier. 2009. Psychopharmaceutical enhancers: enhancing identity? Neuroethics. doi: 10.1007/s12152-008-9031-7.
30. Schöne-Seifert, B., Ach, J., Opolka, U., Talbot, D. (Eds.), 2008. Neuroenhancement- Ethik vor neuen Herausforderungen, Mentis, Paderborn.
31. Beauchamp, T., and J. Childress. 2008. Principles of biomedical ethics. Oxford: Oxford University Press.
32. J. Butcher 2003 Cognitive enhancement raises ethical concerns. Academics urge pre-emptive debate on neurotechnologies Lancet 362 132 133 10.1016/S0140-6736(03)13897-4
33. J. Harris M. Quigley 2008 Humans have always tried to improve their condition Nature 451 521 10.1038/451521b
34. R. de Jongh I. Bolt M. Schermer B. Olivier 2008 Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories Neuroscience and Biobehavioral Reviews 32 760 776 10.1016/j.neubiorev. 2007.12.001
35. A. Szegedi R. Kohnen A. Dienel M. Kieser 2005 Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine BMJ 330 503 10.1136/bmj.38356.655266.82
36. Moncrieff, J., S. Wessely, R., and Hardy. 2004. Active placebos versus antidepressants for depression. Cochrane Database of Systematic Reviews CD003012.
37. J.A. Blumenthal M.A. Babyak K.A. Moore W.E. Craighead, et al. 1999 Effects of exercise training on older patients with major depression Archives of Internal Medicine 159 2349 2356 10.1001/archinte.159.19.2349
38. N.J. Wesensten G. Belenky M.A. Kautz D.R. Thorne, et al. 2002 Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine Psychopharmacology (Berl) 159 238 247 10.1007/s002130100916
39. H. Kaduszkiewicz T. Zimmermann H.P. Beck-Bornholdt H. van den Bussche 2005 Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials Bmj 331 321 323 10.1136/bmj.331.7512.321
40. J.R. Lacasse J. Leo 2005 Serotonin and depression: a disconnect between the advertisements and the scientific literature PLoS Medicine 2 e392 10.1371/journal.pmed.0020392
41. N. Bostrom 2008 Drugs can be used to treat more than disease Nature 451 520 10.1038/451520b
42. I. Kirsch B.J. Deacon T.B. Huedo-Medina A. Scoboria, et al. 2008 Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration PLoS Medicine 5 e45 10.1371/journal.pmed.0050045
43. J. Birks L. Flicker 2006 Donepezil for mild cognitive impairment Cochrane Database of Systematic Reviews 3 CD006104
44. Synofzik, M., Marckmann, G. in press. Dein Wille geschehe? Die Pluralität evaluativer Vorstellungen eines gelingenden Lebens und die Fürsorgepflichten des Arztes., In S Michels, T Potthast, U Wiesing. eds. Pluralität in der Medizin.
45. E. Trindade D. Menon L.A. Topfer C. Coloma 1998 Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis Cmaj 159 1245 1252
46. J.M. Swanson G.R. Elliott L.L. Greenhill T. Wigal, et al. 2007 Effects of stimulant medication on growth rates across 3 years in the MTA follow-up Journal of the American Academy of Child and Adolescent Psychiatry 46 1015 1027 10.1097/chi.0b013e3180686d7e
47. R.A. El-Zein S.Z. Abdel-Rahman M.J. Hay M.S. Lopez, et al. 2005 Cytogenetic effects in children treated with methylphenidate Cancer Letter 230 284 291 10.1016/j.canlet.2005.01.003
48. N.D. Volkow J.M. Swanson 2008 The action of enhancers can lead to addiction Nature 451 520 10.1038/451520a
49. M.S. Ansorge M. Zhou A. Lira R. Hen J.A. Gingrich 2004 Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice Science 306 879 881 10.1126/science.1101678
50. C.J. Whittington T. Kendall P. Fonagy D. Cottrell, et al. 2004 Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data Lancet 363 1341 1345 10.1016/S0140-6736(04) 16043-1
51. T.E. Finucane J.R. Gilstad 2006 Should cholinesterase inhibitors be used to treat Alzheimer's disease Nature Clinical Practice Neurology 2 118 119 10.1038/ncpneuro0130
52. M. Synofzik 2006 Kognition a la carte? Der Wunsch nach kognitionsverbessernden Psychopharmaka in der Medizin Zeitschrift für Ethik in der Medizin 18 37 50 10.1007/s00481-006-0412-3
53. D. DeGrazia 1991 The ethical justification for minimal paternalism in the use of the predictive test for Huntington's disease Journal of Clinical Ethics 2 219 228
54. E.J. Emanuel L.L. Emanuel 1992 Four models of the physician-patient relationship Jama 267 2221 2226 10.1001/jama.267.16.2221